Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial

Trastuzumab is a remarkably effective therapy for patients with human epidermal growth factor receptor 2 (HER2) - positive breast cancer (BC). However, not all women with high levels of HER2 benefit from trastuzumab. By integrating mRNA and protein expression data from Reverse-Phase Protein Array An...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Sonnenblick, Amir, Brohée, Sylvain, Fumagalli, Debora, Rothé, Françoise, Vincent, Delphine, Ignatiadis, Michael, Desmedt, Christine, Salgado, Roberto, Sirtaine, Nicolas, Loi, Sherene, Neven, Patrick, Loibl, Sibylle, Denkert, Carsten, Joensuu, Heikki, Piccart, Martine, Sotiriou, Christos
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2015
Assuntos:
Clinical Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4745800/
https://ncbi.nlm.nih.gov/pubmed/26358523
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados